- Reuters•last year
Belgian biotech group ThromboGenics made a net loss last year as it struggled to build up U.S. business for its main eye drug Jetrea, the company said on Thursday. ThromboGenics said it treated 3,200 U.S. patients with the drug that treats vitreomacular adhesion, which can lead to blindness, against 7,000 patients in 2013. For 2015 ThromboGenics said it expects sales to rise but remain well below 2013 levels, targeting the sale of 3,500 to 4,000 vials of Jetrea. ThromboGenics made a net loss of 51.1 million euros ($54.18 million) last year, against a net profit of 26.4 million euros in 2013, which included a 90 million euro gain from a partnership agreement for sales in Europe.
- Reuters•2 years ago
* Thrombogenics says considers "strategic options" BRUSSELS, Feb 24 (Reuters) - Belgian biotech group Thrombogenics said it is reviewing how to improve sales of its main product in the United States, where sales have disappointed, sending its shares up 14 percent to a four-month high. The group has a marketing agreemeent with Novartis unit Alcon outside the United States but is selling eye drug Jetrea, a treatment for vitreomacular adhesion, an ageing-related condition that can lead to blindness, on its own in the U.S. "We are starting the strategic exercise with an open mind," Chief Executive Patrik De Haes said.